Answers are grounded in this paper and cite their sources.
In cases of coronavirus disease 2019 (COVID-19), favipiravir is commonly included to the therapy regimen. Drug interactions between favipiravir and other COVID-19 therapy drugs are frequently researched. However, no research on possible drug interactions between Favipiravir and radiocontrast agents, which have become almost crucial in diagnostic processes while not being part of the treatment, has been found.
No takes yet. Share an insight, caveat, or question.
Aydın et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: